Adial Pharmaceuticals Inc
$ 0.32
0.70%
03 Dec - close price
- Market Cap 7,558,500 USD
- Current Price $ 0.32
- High / Low $ 0.32 / 0.30
- Stock P/E N/A
- Book Value 0.19
- EPS -0.60
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.79 %
- ROE -1.55 %
- 52 Week High 1.30
- 52 Week Low 0.22
About
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Charlottesville, Virginia, dedicated to developing novel therapies for substance use disorders, with a primary focus on alcohol use disorder. The company’s lead candidate, AD04, represents a groundbreaking approach in a largely underserved market, aiming to mitigate the pressing health challenges associated with addiction. Through its innovative pipeline and commitment to improving patient outcomes, Adial is strategically positioned to offer transformative solutions in addiction treatment and prevention, potentially reshaping the landscape of therapies available for affected individuals.
Analyst Target Price
$2.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-18 | 2025-08-13 | 2025-05-12 | 2025-03-31 | 2024-11-12 | 2024-08-13 | 2024-05-14 | 2024-02-20 | 2023-11-14 | 2023-08-21 | 2023-05-12 | 2023-03-30 |
| Reported EPS | -0.08 | -0.18 | -0.34 | -0.15 | -0.38 | -0.59 | -0.62 | -1.35 | -1.18 | 0.96 | -0.11 | -0.105 |
| Estimated EPS | -0.14 | -0.39 | -0.495 | -0.33 | -0.44 | -0.53 | -0.33 | -0.76 | -1.13 | -1.5 | -0.14 | -0.15 |
| Surprise | 0.06 | 0.21 | 0.155 | 0.18 | 0.06 | -0.06 | -0.29 | -0.59 | -0.05 | 2.46 | 0.03 | 0.045 |
| Surprise Percentage | 42.8571% | 53.8462% | 31.3131% | 54.5455% | 13.6364% | -11.3208% | -87.8788% | -77.6316% | -4.4248% | 164% | 21.4286% | 30% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADIL
2025-11-18 20:23:02
Adial Pharmaceuticals narrowed its quarterly loss and secured FDA approval for Phase 3 trials of its lead drug, AD04, for alcohol use disorder. This progress, coupled with cost-cutting and a partnership for a diagnostic test, has boosted analyst optimism and the company's price outlook. Potential US policy changes regarding clinical trial outcomes could further enhance AD04's market potential and foster innovation in the biotech sector.
2025-11-14 08:30:00
Adial Pharmaceuticals reported its third-quarter 2025 financial results and provided a business update, highlighting significant progress towards FDA approval and commercialization of AD04 for Alcohol Use Disorder (AUD). Key achievements include a successful End of Phase 2 meeting with the FDA, validation of a cheek swab genetic testing method with Genomind, and strong financial management maintaining cash reserves into Q2 2026. The company anticipates AD04 will be the first genetically targeted therapy for AUD, addressing a significant unmet medical need.
2025-11-14 08:30:00
Adial Pharmaceuticals reported its Q3 2025 financial results and provided a business update, highlighting a successful End of Phase 2 (EOP2) meeting with the FDA for its lead drug AD04, which provided guidance on an adaptive Phase 3 design and confirmed the cheek swab Genomind test as Non-Significant Risk for Phase 3 use. The company reported $4.6 million in cash as of September 30, 2025, with an expected cash runway into Q2 2026, and a 50% year-over-year decrease in R&D expenses. Adial also filed a provisional patent update to protect core assets through 2045, aiming to target biomarker-positive AUD patients with AD04.
2025-10-17 13:00:00
Adial Pharmaceuticals announced that its CEO, Cary Claiborne, was a featured guest on the Emmy Award-winning Big Biz Show. The show, which aired on October 15, 2025, discussed the clinical-stage biopharmaceutical company's focus on treatments for addiction and related disorders, particularly its lead drug AD04 for Alcohol Use Disorder. The interview was broadcast across various platforms including Fox Business, NBCUniversal, and numerous streaming and radio services.
2025-10-17 13:00:00
Adial Pharmaceuticals announced that its CEO, Cary Claiborne, was a featured guest on "The Big Biz Show," a nationally syndicated radio and TV program. The show, which aired on October 15, 2025, discussed the company's work in developing therapies for addiction and related disorders, particularly its lead drug candidate AD04 for Alcohol Use Disorder. The company highlighted its ongoing efforts and the promising results from its ONWARD™ pivotal Phase 3 clinical trial.
2025-10-16 18:16:04
A new report from DelveInsight highlights that over 30 pharmaceutical and biotech companies are developing more than 30 therapeutic candidates for Alcohol Use Disorder (AUD). The report, "Alcohol Use Disorder Pipeline Insight 2025," provides an overview of clinical trial progress, emerging therapies, and key company initiatives, detailing pipeline candidates such as AD04, Sunobinop, and BICX104. Recent regulatory developments include the FDA recognizing a two-level Risk Drinking Level reduction as a valid primary endpoint for AUD trials and positive feedback for Awakn's AWKN002 via the 505(b)(2) pathway.
